Our Collaborators

BeiGene

In August 2018, SpringWorks and BeiGene entered into a global clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of combining BeiGene’s investigational RAF-dimer inhibitor, lifirafenib (BGB-283) with SpringWorks Therapeutics’ investigational MEK inhibitor, mirdametinib, in a range of genetically-defined solid tumors. A Phase 1b clinical trial is enrolling patients with advanced solid tumors that harbor mutations in RAS, RAF, and other MAPK pathway genes.

MapKure

MapKure is a clinical-stage company created in 2019 to develop precision medicines for patients with life-threatening diseases, with an initial focus on cancer. MapKure is jointly owned by SpringWorks and BeiGene, and is developing BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations, including V600 B-RAF mutations, non-V600 B-RAF mutations and RAF fusions. These mutations and fusions have been identified in a number of solid tumors to be drivers of cancer growth, including in non-small cell lung cancer, colorectal cancer, thyroid cancer and brain tumors.

GlaxoSmithKline

In June 2019, SpringWorks and GlaxoSmithKline entered into a global clinical collaboration agreement to conduct a Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the combining SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat with GlaxoSmithKline’s anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), BLENREP (belantamab mafodotin-blmf) (formerly GSK2857916), in patients with relapsed or refractory multiple myeloma.

Allogene

In January 2020, SpringWorks signed a clinical collaboration with Allogene Therapeutics to evaluate nirogacestat in combination with ALLO-715, Allogene’s investigational BCMA allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapy in patients with relapsed or refractory multiple myeloma.

Janssen

In September 2020, SpringWorks entered into a clinical collaboration with Janssen Biotech, Inc. (Janssen) to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of combining nirogacestat in combination with Janssen’s investigational bispecific antibody targeting BCMA and CD3, teclistamab, in patients with relapsed or refractory multiple myeloma.

Precision BioSciences, Inc.

In September 2020, SpringWorks and Precision BioSciences entered into a clinical collaboration to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Precision BioSciences’ investigational allogeneic chimeric antigen receptor (CAR) T cell therapy which targets BCMA, PBCAR269A, in patients with relapsed or refractory multiple myeloma.

Pfizer

In October 2020, SpringWorks and Pfizer entered into a clinical collaboration to conduct a Phase 1b/2 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Pfizer’s investigational BCMA CD3 bispecific antibody, PF‐06863135, in patients with relapsed or refractory multiple myeloma.

Fred Hutchinson Cancer Research Center

In September 2020, SpringWorks Therapeutics entered into a sponsored research agreement with the Fred Hutchinson Cancer Research Center (Fred Hutch) to further evaluate nirogacestat to modulate BCMA and potentiate BCMA-targeted therapies in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch.

Children’s Oncology Group

In September 2020, SpringWorks and the Children’s Oncology Group (COG) entered into a collaboration to conduct a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumors.